Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ELOA3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5101331
Description
Antibody detects endogenous levels of total ELOA3.
The elongin (SIII) complex is composed of a transcriptionally active A subunit and two small regulatory subunits, B and C. This complex stimulates the transcription elongation rate of RNA polyermase II by suppressing time spent at template-encoded arresting sites along DNA. Elongin A3, also known as RNA polymerase II transcription factor SIII subunit A3 and Transcription elongation factor B polypeptide 3C, is a 546 amino acid nuclear protein that functions as a general transcription elongation factor that increases RNA polymerase II transcription elongation and forms a stable complex with Elongin BC. In contrast to Elongin A, transcriptional activity of Elongin A3 is not stimulated by Elongin BC. Elongin A3 contains one TFIIS N-terminal domain and is ubiquitously expressed in human tissue.
Specifications
ELOA3 | |
Polyclonal | |
Unconjugated | |
ELOA3 | |
eloA3; Elongin A3; ElonginA3; Elongin-A3; HsT829; RNA polymerase II transcription factor SIII subunit A3; TCEB3C; TCEB3L2; Transcription elongation factor B polypeptide 3C; transcription elongation factor B polypeptide 3C (elongin A3); transcription elongation factor B subunit 3C | |
A synthesized peptide derived from human ELOA3(Accession Q8NG57), corresponding to amino acid residues A383-K433. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q8NG57 | |
Rabbit | |
Affinity chromatography | |
RUO | |
162699 | |
-20°C | |
Liquid |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction